Literature DB >> 10931058

Oesophageal resection for high-grade dysplasia in Barrett's oesophagus.

G Zaninotto1, A R Parenti, A Ruol, M Costantini, S Merigliano, E Ancona.   

Abstract

BACKGROUND: The aims of this study were to evaluate the prevalence of invasive cancer in patients with high-grade dysplasia in Barrett's oesophagus and to verify whether a second endoscopy with multiple biopsies could improve the accuracy of preoperative diagnosis. In addition, the mortality, morbidity and survival rates in patients with high-grade dysplasia having oesophageal resection were recorded.
METHODS: Fifteen patients were observed from 1982 to 1998; the first seven patients were offered primary oesophageal resection after diagnosis. The other eight patients underwent a second endoscopy with a median of 12 biopsies examined. All later underwent oesophageal resection.
RESULTS: Invasive adenocarcinoma was found in five patients, with a minimal difference between the first and second periods (two of seven versus three of eight). There were no perioperative deaths. Early morbidity was observed in eight patients and late morbidity in four. The actuarial survival rate was 79 per cent at 5 years. The Karnofsky status was unchanged from preoperative values in 13 of 15 patients after a median follow-up of 46 months.
CONCLUSION: These patients with high-grade dysplasia had a 33 per cent probability of harbouring invasive oesophageal carcinoma but even a second endoscopy failed to identify patients with invasive tumour. Oesophagectomy was performed with no deaths and remains a rational treatment in patients fit for surgery.

Entities:  

Mesh:

Year:  2000        PMID: 10931058     DOI: 10.1046/j.1365-2168.2000.01470.x

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  20 in total

1.  Ablative mucosectomy is the procedure of choice to prevent Barrett's cancer.

Authors:  H Barr
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

2.  Can extent of high grade dysplasia in Barrett's oesophagus predict the presence of adenocarcinoma at oesophagectomy?

Authors:  M S Dar; J R Goldblum; T W Rice; G W Falk
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

3.  Barrett's Esophagus: A Review of Biology and Therapeutic Approaches.

Authors:  Panteleimon Kountourakis; Jaffer A Ajani; Marta Davila; Jeffrey H Lee; Manoop S Bhutani; Julie G Izzo
Journal:  Gastrointest Cancer Res       Date:  2012-03

Review 4.  Endoscopic therapy for Barrett's oesophagus.

Authors:  H Barr; N Stone; B Rembacken
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

5.  Esophagectomy for Barrett's esophagus: indications, techniques, and outcome.

Authors:  Ninh T Nguyen; Ken Chang; Tarlan Nahidi; Samuel E Wilson; James D Luketich
Journal:  Curr Treat Options Gastroenterol       Date:  2006-02

6.  Predictive factors of coexisting cancer in Barrett's high-grade dysplasia.

Authors:  C Tharavej; J A Hagen; J H Peters; G Portale; J Lipham; S R DeMeester; C G Bremner; T R DeMeester
Journal:  Surg Endosc       Date:  2006-01-25       Impact factor: 4.584

Review 7.  High-grade dysplasia in Barrett's oesophagus. The case against oesophageal resection.

Authors:  Hugh Barr
Journal:  Ann R Coll Surg Engl       Date:  2007-09       Impact factor: 1.891

Review 8.  Endotherapy for Barrett's esophagus with high-grade dysplasia and intramucosal carcinoma.

Authors:  Drew B Schembre
Journal:  J Gastrointest Surg       Date:  2009-03-26       Impact factor: 3.452

9.  Expert pathology review and endoscopic mucosal resection alters the diagnosis of patients referred to undergo therapy for Barrett's esophagus.

Authors:  Katie Ayers; Chanjuan Shi; Kay Washington; Patrick Yachimski
Journal:  Surg Endosc       Date:  2013-02-07       Impact factor: 4.584

Review 10.  Preemptive surgery for premalignant foregut lesions.

Authors:  Rohit R Sharma; Mark J London; Laura L Magenta; Mitchell C Posner; Kevin K Roggin
Journal:  J Gastrointest Surg       Date:  2009-06-10       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.